ERYTECH
hold a presentation
to
the
conference
HC Wainwright
Global Investment
Lyons (
France
), and Cambridge, MA (US)
the
1
7
May 2
022
–
ERYTECH
Pharmaceuticals (Euronext
&
Nasdaq
: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells (RBCs),
announcement
has
a
today
that its Managing Director, Gil Beyen, will make a presentation on the occasion of the
conference
HC Wainwright Global Investment
. The conference will be held
in hybrid format
May 23-26
2022
at Miami
in the USA
.
The corporate presentation will take place face-to-face on Wednesday May 25 at 10:30 a.m. ET (4:30 p.m. CEST) and will be accessible post-meeting on the conference website.
Gil Beyen will be available for one-on-one meetings with investors on May 24, 25 and 26, 2022.
If you would like to arrange a one-on-one meeting or register, please contact the conference representative.
For more information on the conference
HC Wainwright 23
rd
Global Investment
please visit the event website https://hcwevents.com/globalconference/ .
About ERYTECH and eryaspase
(GRASPA®)
www.erytech.com
Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH focuses primarily on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.
The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. A Phase 2 study in metastatic triple-negative breast cancer and an investigator-sponsored Phase 1 clinical study in the first-line treatment of advanced pancreatic cancer are ongoing.
Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer. Eryaspase is not approved in any country.
ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and believes it has the means to produce for patients in the United States thanks to its long-term supply agreement with Catalent, operating from ERYTECH’s former GMP production site in Princeton, New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
CONTACTS
|
ERYTECH Eric Soyer Chief Financial Officer and Director of Operations |
NewCap Mathilde Bohin/Louis-Victor Delouvrier Investor Relations Nicolas Merigeau Media Relations |
+33 (0)4 78 74 44 38 | +33 (0)1 44 71 94 94 |
Enclosed
CP_ERYTECH_2022 HCW Conf_Invest_FR